EIT Pharma presented new analyses from the lonafarnib development program for Chronic Hepatitis Delta (CHD) at EASL Congress ...
Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today ...
Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that new 48-week data from the IMPACT Phase 2b ...
Alcohol policy and liver disease were central at this EASL 2026 session. Experts called for stronger labelling and prevention ...
New data showed durable hepatitis D virus RNA suppression through 96 weeks with tobevibart plus elebsiran, while higher BMI appeared to affect ALT normalization. Two posters presented at EASL 2026 ...
Supplement-induced liver injury is rising as wellness supplement use grows globally. Learn more about the risks highlighted at EASL 2026.
Long-term follow up data from the Phase 1 study of pevifoscorvir sodium continues to suggest a reduction in the cccDNA reservoirData on the ...
With a historic WHO resolution adopted this week giving countries, for the first time, a mandate to address liver disease ...
Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced ...
May 13, 2026 - Inventiva (Euronext Paris and NASDAQ: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results